c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.
about
Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signalingTargeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastomaEffects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2A U87-EGFRvIII cell-specific aptamer mediates small interfering RNA delivery.DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification.Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.Glial progenitors as targets for transformation in glioma.The future of high-grade glioma: Where we are and where are we going.MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell linesEndosomal Na+/H+ exchanger NHE5 influences MET recycling and cell migration.Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.High levels of c-Met is associated with poor prognosis in glioblastoma.Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls.The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme.Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.MET gain in diffuse astrocytomas is associated with poorer outcome.Mesenchymal/radioresistant traits in granular astrocytomas: evidence from a combined clinical and molecular approach.Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma.
P2860
Q27011423-E8B3E90B-DD00-497B-AD17-DE452AA438B1Q27022941-BA2C6119-8CC4-402D-B55A-6D9741CCE80CQ28487568-EEF2C525-A9A3-49EC-A36E-569706F10552Q33733546-52AACB7E-B59A-4CF4-AB40-48A55BD91666Q34203095-B64F89E1-2BCB-4750-B269-EC174276D113Q34236834-20DF1582-D0CA-421D-BDAD-37A171557D40Q34735661-E0AF52ED-BB97-499A-84F3-3DBE8E884C3AQ35114090-D31CB3B2-76C0-4D59-B835-998219C2F966Q35208173-48280B52-0E38-4F08-9A2D-5939370335E9Q36572692-314BA4EA-0395-4521-9643-CD94E473581FQ38812830-6D5BF346-B55C-4372-9C6D-0BB9AF7E1527Q38896220-C644C497-AED6-4C92-8832-144DF01D4C29Q39212474-DBBC2A23-C8A5-4FFB-9AF0-E0CF16CDC7EDQ40226917-E86E2A55-C9F3-4AA5-BDEE-1BF5F918E21DQ43819146-7C900CDA-3D2D-4153-8333-F4FD82C73DAFQ45070195-047A0366-066C-42B4-AA32-42695D28DAC1Q45839064-4A7B6774-67A4-4D3C-AE5D-10F9F21A7796Q47885282-A5ED147E-F71B-4F61-9719-5D453D37384AQ52147579-9FD4C6A3-0142-4DFF-A045-32D9D2EBADD5Q54210243-2BE9FD37-EC5D-4249-8FA0-66D0662893FB
P2860
c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
c-Met expression is associated ...... with glioblastoma multiforme.
@en
c-Met expression is associated ...... with glioblastoma multiforme.
@nl
type
label
c-Met expression is associated ...... with glioblastoma multiforme.
@en
c-Met expression is associated ...... with glioblastoma multiforme.
@nl
prefLabel
c-Met expression is associated ...... with glioblastoma multiforme.
@en
c-Met expression is associated ...... with glioblastoma multiforme.
@nl
P2093
P1476
c-Met expression is associated ...... with glioblastoma multiforme.
@en
P2093
Chigang Du
Guangyu Zhao
Kang Zhang
Shangchen Xu
P304
P356
10.1016/J.JOCN.2010.05.010
P577
2010-09-15T00:00:00Z